Takeda Pharmaceutical Net Income 2010-2022 | TAK
Takeda Pharmaceutical annual/quarterly net income history and growth rate from 2010 to 2022. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
- Takeda Pharmaceutical net income for the quarter ending December 31, 2022 was $0.846B, a 66.37% increase year-over-year.
- Takeda Pharmaceutical net income for the twelve months ending December 31, 2022 was $1.396B, a 69.59% decline year-over-year.
- Takeda Pharmaceutical annual net income for 2022 was $2.048B, a 42.07% decline from 2021.
- Takeda Pharmaceutical annual net income for 2021 was $3.534B, a 768.38% increase from 2020.
- Takeda Pharmaceutical annual net income for 2020 was $0.407B, a 58.56% decline from 2019.
Takeda Pharmaceutical Annual Net Income
(Millions of US $) |
| 2022 |
$2,048 |
| 2021 |
$3,534 |
| 2020 |
$407 |
| 2019 |
$982 |
| 2018 |
$1,682 |
| 2017 |
$1,069 |
| 2016 |
$665 |
| 2015 |
$-1,327 |
| 2014 |
$1,067 |
| 2013 |
$1,588 |
| 2012 |
$1,577 |
| 2011 |
$2,986 |
| 2010 |
$3,202 |
| 2009 |
$2,392 |
Takeda Pharmaceutical Quarterly Net Income
(Millions of US $) |
| 2022-12-31 |
$846 |
| 2022-09-30 |
$445 |
| 2022-06-30 |
$809 |
| 2022-03-31 |
$-703 |
| 2021-12-31 |
$508 |
| 2021-09-30 |
$418 |
| 2021-06-30 |
$1,823 |
| 2021-03-31 |
$1,843 |
| 2020-12-31 |
$887 |
| 2020-09-30 |
$38 |
| 2020-06-30 |
$767 |
| 2020-03-31 |
$391 |
| 2019-12-31 |
$-296 |
| 2019-09-30 |
$501 |
| 2019-06-30 |
$-188 |
| 2018-12-31 |
$336 |
| 2018-06-30 |
$720 |
| 2017-06-30 |
$1,303 |
| 2016-06-30 |
$926 |
| 2015-06-30 |
$202 |
| 2015-03-31 |
$-1,892 |
| 2014-12-31 |
$156 |
| 2014-09-30 |
$260 |
| 2014-06-30 |
$326 |
| 2014-03-31 |
$-43 |
| 2013-12-31 |
$457 |
| 2013-09-30 |
$360 |
| 2013-06-30 |
$296 |
| 2013-03-31 |
$462 |
| 2012-12-31 |
$236 |
| 2012-09-30 |
$409 |
| 2012-06-30 |
$1,119 |
| 2012-03-31 |
$-460 |
| 2011-12-31 |
$322 |
| 2011-09-30 |
$775 |
| 2011-03-31 |
$394 |
| 2010-03-31 |
$426 |
| 2009-09-30 |
$-1 |
| 2009-03-31 |
$705 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Drug Manufacturing |
$52.152B |
$31.791B |
|
Takeda Pharmaceutical Company Limited operates as a research-based pharmaceutical company, engaged in manufacturing, marketing, and importing/exporting pharmaceutical drugs. Takeda's core business comprise of ethical drugs and its portfolio includes lansoprazole for the treatment of peptic ulcers, leuprolide acetate for the treatment of prostate cancer and endometriosis, pioglitazone hydrocholoride for the treatment of diabetes, and candesartan cilexetil for the treatment of hypertension. The Company promotes enhancing R&D pipeline, while concentrating its management resources to the four core therapeutic areas: lifestyle-related diseases, oncology and urological diseases, central nervous system disease and gastroenterological diseases. It operates in two segments- Ethical drug business and Consumer healthcare business. Consumer healthcare business provides Alinamin (vitamin B1 derivative preparations, etc.), Benza (cold remedies). Takeda Pharmaceutical Company Limited is headquartered in Osaka, Japan.
|
